Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Obes Pillars ; 1: 100005, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38085928

RESUMO

Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) on Nutrition and Physical Activity provides clinicians an overview of nutrition and physical activity principles applicable to the care of patients with increased body fat, especially those with adverse fat mass and adiposopathic metabolic consequences. Methods: The scientific information and clinical guidance is based upon referenced evidence and derived from the clinical perspectives of the authors. Results: This OMA CPS on Nutrition and Physical Activity provides basic clinical information regarding carbohydrates, proteins, fats (including trans fats, saturated fats, polyunsaturated fats, and monounsaturated fats), general principles of healthful nutrition, nutritional factors associated with improved health outcomes, and food labels. Included are the clinical implications of isocaloric substitution of refined carbohydrates with saturated fats and vice-versa, as well as definitions of low-calorie, very low-calorie, carbohydrate-restricted, and fat-restricted dietary intakes. Specific dietary plans discussed include carbohydrate-restricted diets, fat-restricted diets, very low-calorie diets, the Mediterranean diet, Therapeutic Lifestyle diet, Dietary Approaches to Stop Hypertension (DASH), ketogenic (modified Atkins) diet, Ornish diet, Paleo diet, vegetarian or vegan diet (whole food/plant-based), intermittent fasting/time restricted feeding, and commercial diet programs. This clinical practice statement also examines the health benefits of physical activity and provides practical pre-exercise medical evaluation guidance as well as suggestions regarding types and recommended amounts of dynamic (aerobic) training, resistance (anaerobic) training, leisure time physical activity, and non-exercise activity thermogenesis (NEAT). Additional guidance is provided regarding muscle physiology, exercise prescription, metabolic equivalent tasks (METS), and methods to track physical activity progress. Conclusion: This Obesity Medicine Association Clinical Practice Statement on Nutrition and Physical Activity provides clinicians an overview of nutrition and physical activity. Implementation of appropriate nutrition and physical activity in patients with pre-obesity and/or obesity may improve the health of patients, especially those with adverse fat mass and adiposopathic metabolic consequences.

2.
Nurs Clin North Am ; 56(4): 495-509, 2021 12.
Artigo em Inglês | MEDLINE | ID: mdl-34749890

RESUMO

Obesity is a chronic, progressive, and relapsing disease state the management of which includes a comprehensive, long-term management plan. Comprehensive management of obesity includes 4 key components of care: nutrition, behavioral intervention, physical activity, and clinical management. This article reviews current evidence-based treatment of obesity and key components for all clinicians to have knowledge of.


Assuntos
Terapia Comportamental , Dieta Mediterrânea , Medicina Baseada em Evidências , Exercício Físico , Obesidade/terapia , Humanos , Estado Nutricional
3.
Postgrad Med ; 133(3): 310-319, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33151791

RESUMO

Obesity is a chronic, relapsing metabolic disease, linked to a number of health risks and serious complications. Although highly prevalent in adults in the United States, it is underdiagnosed and untreated. Primary care providers (PCPs) are uniquely poised to diagnose and treat patients with obesity, using a selection of treatment strategies including lifestyle modifications and pharmacotherapies. As a physiological regulator of appetite and energy intake, the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide 3.0 mg is approved for chronic weight management in individuals with overweight (pre-obesity) or obesity. In this review, we provide an overview of the clinical data supporting the use of liraglutide 3.0 mg, as well as practical advice for PCPs on the initiation and maintenance of treatment over the long term. This also covers the management of side effects and how to manage patient expectations over time.


Assuntos
Fármacos Antiobesidade/uso terapêutico , Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas , Liraglutida/uso terapêutico , Obesidade/tratamento farmacológico , Fármacos Antiobesidade/efeitos adversos , Fármacos Antiobesidade/farmacologia , Índice de Massa Corporal , Ensaios Clínicos Fase III como Assunto , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/epidemiologia , Dieta Redutora/métodos , Dislipidemias/epidemiologia , Humanos , Hipertensão/epidemiologia , Liraglutida/efeitos adversos , Liraglutida/farmacologia , Obesidade/complicações , Obesidade/epidemiologia , Ensaios Clínicos Controlados Aleatórios como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...